Abstract 5096
Background
The NKG2D receptor is a type II transmembrane glycoprotein playing an important role in anti-tumor responses. In humans, NKG2D binds to eight ligands, MHC class I–related chain MICA and B and unique long 16 (UL16)-binding proteins ULBP 1-6. The surface expression of NKG2D ligands (NKG2DL) is highly regulated to avoid inappropriate immune responses in physiological conditions but is induced by various stress situations such as malignant transformation or inflammation. NKG2DL expression on tumors has been reported in the literature. However, a systematic study on all NKG2DL in a large array of normal tissues and tumor samples is lacking. Celyad is pursuing the clinical development of NKG2D based chimeric antigen receptor (CAR) T cell therapy and robust data are thus required to adequately support this work.
Methods
We performed an extensive immunohistochemistry study on primary tumors and normal adjacent tissues from patients suffering from pancreatic, breast, ovarian, bladder, colorectal and lung carcinomas and on a series of normal tissues from non-cancer patients.
Results
MICA/B were the most frequently and highly expressed. Interestingly the subset of triple negative breast cancers (TNBC) showed strong membranous staining for all NKG2DL on tumor cells making this patient subpopulation a very attractive therapeutic target for NKG2D-based therapies. There was no clear correlation between the expression of NKG2DL and the clinical stage of the tumors indicating that every stage of the diseases could be targeted. In bladder, TNBC, CRC and pancreatic tumors, tumor cells were frequently stained for multiple NKG2DL implying that these tumors would not be susceptible to immune escape. Tumor-associated fibrovascular structures displayed generally membranous staining within the endothelial compartment suggesting that NKG2D-based CAR T therapy can target simultaneously both the tumor and the tumor microenvironment.
Conclusions
In conclusion, this extensive immunohistochemistry study supports the concept of targeting NKG2DL for cancer therapy.
Clinical trial identification
Legal entity responsible for the study
Celyad SA.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
S. Agaugue, D. Gilham: Employee: Celayd SA. A. Hargreaves: Employee: Pathcelerate SA. P. De Sousa: Employee: PDC lines SA. All other authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract